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To assess the relationship between carriage of APOE ε4 allele and evolution of white matter hyper-
intensities (WMHs) volume, we longitudinally studied 339 subjects from the Alzheimer’s Disease Neu-
roimaging Initiative cohort with diagnoses ranging from normal controls to probable Alzheimer’s disease
(AD). A purpose-built longitudinal automatic method was used to segment WMH using constraints
derived from an atlas-based model selection applied to a time-averaged image. Linear mixed models
were used to evaluate the differences in rate of change across diagnosis and genetic groups. After
adjustment for covariates (age, sex, and total intracranial volume), homozygous APOE ε4ε4 subjects had a
signiﬁcantly higher rate of WMH accumulation (22.5% per year 95% CI [14.4, 31.2] for a standardized
population having typical values of covariates) compared with the heterozygous (ε4ε3) subjects (10.0%
per year [6.7, 13.4]) and homozygous ε3ε3 (6.6% per year [4.1, 9.3]) subjects. Rates of accumulation
increased with diagnostic severity; controls accumulated 5.8% per year 95% CI: [2.2, 9.6] for the stan-
dardized population, early mild cognitive impairment 6.6% per year [3.9, 9.4], late mild cognitive
impairment 12.5% per year [8.2, 17.0] and AD subjects 14.7% per year [6.0, 24.0]. Following adjustment for
APOE status, these differences became nonstatistically signiﬁcant suggesting that APOE ε4 genotype is the
major driver of accumulation of WMH volume rather than diagnosis of AD.
 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The APOE gene, and speciﬁcally its ε4 allelic variant, has an
important dose-dependent association with Alzheimer’s disease
(AD) risk (Verghese et al., 2011). APOE ε4 is associated with
increased cerebral amyloid plaque deposition and amount of white
matter hyperintensities (WMHs).roup, 8th Floor, Malet Place
alet Place, WC1E 7JE London,
0255.
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er Inc. This is an open access articWMHs are associated with increasing age in apparently healthy
elderly subjects and inversely related to executive function and
processing speed (Mortamais et al., 2013). They are thought to be a
marker of cerebral small vessel disease, and possible pathophysi-
ological explanations for the imaging change include partial
ischemia of the tissue and degradation of the blood-brain barrier
(Wardlaw et al., 2015). In line with a possible vascular etiology,
WMHs are associated with cardiovascular risk factors such as hy-
pertension (Abraham et al., 2016), diabetes (Brundel et al., 2014),
and smoking (Power et al., 2015). However, WMH also occur with
greater frequency in AD patients (Holland et al., 2008; Provenzano
et al., 2013) compared with normal controls. Interestingly, from the
point of view of AD, parenchymal WMH can also be related to ce-
rebral amyloid angiopathy (CAA), where amyloid protein affects
blood vessel function, potentially impairing the supply of oxygen
and nutrients to the brain (Esiri et al., 2015; Greenberg, 2002;le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Flowchart of the subject selection. Red boxes reﬂect the number of discarded
subjects. Abbreviations: AD, Alzheimer’s disease; EMCI, early mild cognitive impair-
ment; LMCI, late MCI; NC, normal control. (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the Web version of this article.)
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gated the link between WMH and APOE status have led to contra-
dictory results (Benedictus et al., 2013; Brickman et al., 2014; Esiri
et al., 2015; Kim et al., 2013). Many of those studies, however,
were hampered by a cross-sectional design.
We studied the association between APOE ε4 status andWMH in
a longitudinal framework, for a population with limited cardio-
vascular risk factors but heterogeneous in terms of AD diagnoses.
We used a novel approach for automatic longitudinal WMH lesion
segmentation, with the aim of providing greater precision to the
assessment of WMH changes and thereby clarifying the relevance
of APOE ε4 in the accumulation of WMH.
2. Methods
2.1. Data selection
Data used were obtained from the Alzheimer’s Disease Neuro-
imaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI
project was launched in 2003 as a public-private partnership,
whose primary goal has been to test whether serial magnetic
resonance imaging, positron emission tomography (PET), other
biological markers, and clinical and neuropsychological assessment
can be combined to measure the progression of mild cognitive
impairment (MCI) and early AD. Information about the study can be
found at www.adni-info.org. Data collection was approved by each
center’s Institutional Review Board, and participants gave written
informed consent at time of enrolment.
At their initial visit, following clinical and neuropsychological
assessment, each subject was given 1 of 4 diagnoses: normal con-
trol (NC), early MCI (EMCI), late MCI (LMCI), or probable AD. To be
included in the ADNI study, newly recruited participants had to
score 4 or below on the modiﬁed Hachinski scale for cerebrovas-
cular disease, thereby limiting the range of WMH at baseline.
Furthermore, included MCI subjects had to present with an
amnestic form of cognitive decline as opposed to a vascular form
associated with executive dysfunction.
We selected subjects from the ADNI database using criteria
based on available quality scans. Only subjects for whom at least 4
imaging time points with adequate ﬂuid attenuated inversion re-
covery images were selected. To avoid introducing any pre-
processing bias into the analysis, only subjects with T1 scans
preprocessed with N3 histogram sharpening and corrected for B1
bias ﬁeld and gradient nonlinearity were used. Subjects were
further excluded if they had poor quality imaging. Fig. 1 presents
the ﬂowchart of data selection. According to the ADNI record of
adverse events, none of the selected subjects suffered from stroke
during the course of the study.
The genotyping for APOEwas performed at screening visit using
DNA extracted by Cogenic using a 3-mL aliquot of EDTA blood,
while the level of corticospinal ﬂuid (CSF) Ab is obtained using the
xMAP Luminex platform and the Innogenetics/Fujirebio AlzBio3
immunoassay kits. Further details on the diagnostic procedure,
scanning and imaging protocols as well as genotyping and Ab
measurement can be found at http://www.adni-info.org/scientists/
ADNIStudyProcedures.aspx.
2.2. Image analysis
We developed a novel fully automatic multimodal lesion seg-
mentation pipeline to jointly analyze all longitudinal imaging time
points together. Instead of considering each time point indepen-
dently and thereby increasing the variability in the longitudinal
assessment, an average image was iteratively created. Alignment
was achieved through matching intensities of normal tissue in theimages in an iterative procedure involving steps of afﬁne and
nonrigid registration using jointly the 2 pulse sequences, the ﬂuid
attenuated inversion recovery sequence being afﬁnely aligned to the
T1-weighted image (Modat et al., 2010, 2014). Based on the results
of an existing method (Sudre et al., 2015) applied to the average
image, theWMH segmentation at each time point was generated. In
brief, this method builds a Bayesian probabilistic data model based
on an evolving Gaussianmixturemodel, which is able to account for
observation outliers and incorporates anatomical priors and
contextual information for the average appearance model. The
model was then further used to constrain the segmentation at each
time point. To do so, the model structure (number of Gaussian
components) and its associated parameters and resultant segmen-
tation were used to initialize the optimization of the data modeling
in the original space of each time point and provide a priori infor-
mation. Probabilistic lesion maps were obtained from the Gaussian
mixture model based on the evaluation of outlierness when
compared to the healthy WM and integrated to determine the ﬁnal
WMH volumes.
Fig. 2 displays the ﬂowchart of the longitudinal framework with
its 3 main steps: average image building, probabilistic model se-
lection, and constraint over the individual time points.
The total intracranial volume (TIV), that included total brain
volume, ventricles, and CSF between the brain and meninges, was
automatically obtained using a previously described method
Fig. 2. Flowchart of the longitudinal framework and its 3 main components. The red ﬁlled boxes refer to the space of the average image, whereas the blue boxes correspond to the
set of individual time point images and the green boxes to performed actions. Abbreviation: WMH, white matter hyperintensity. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the Web version of this article.)
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generated from the average image, was used as a covariate in
statistical analyses.
2.3. Statistical analysis
To assess how our method compared to the ﬁrst measurements
obtained through the method detailed by De Carli et al. (2013) (UC
Davis’ method) made available on the ADNI database, we calculated
Pearson’s and Spearman’s correlation coefﬁcients. In addition, we
assessed agreement between methods through construction of the
geometric mean of the ratio of the volumes together with 95%
reference ranges. Since differences in volumes may be related to
lesion size, we reported these ratios and corresponding reference
ranges separately in low versus high lesion volumes (bisected at the
median of the mean of the 2 volumes).
All the statistical analyses were performed using Stata 12 v1.
Owing to the skewness of the WMH volumes, they were log-
transformed before analysis. Cross-sectional analysis of the base-
line log-transformed WMH volumes was performed using linear
regression models including age, TIV, and sex as covariates in all
models. Four models were ﬁtted: these included diagnosis status
(model ASTD), genetic status (model ASTG), genetic and diagnosis
status (model ASTGD), and genetic status and CSF Ab 42 concen-
tration (model ASTGAb) as predictor variables. F-tests were used to
assess differences between groups after adjustment for covariates.
Fitted group speciﬁc means, standardized to a 50/50 mixture of
males and females at age 72.2 years with a TIV of 1552mL (with 95%
CI), were also computed and back-transformed. These age and TIV
valueswere chosen as theywere themean values across all subjects.
Longitudinal changes in WMH volume were assessed using
linear mixed models, with random intercepts and slopes, for the
repeated measures. Linear mixed models, provided that they are
properly speciﬁed, appropriately allow for the nonindependence of
repeated measures from the same subject (Verbeke andMolenberghs, 2000). The dependent variable in all models was
the log-transformed volume of WMH with time from initial mea-
surement treated as both a ﬁxed and random effect (thereby
allowing slopes to differ between subjects). Other ﬁxed effects were
group terms (diagnosis and/or APOE status) and group-time inter-
action terms (thereby allowing mean rates of change to differ be-
tween groups) and age, TIV, and sex and their interactions with
time. One model (model ASTG) investigated differences in slope
between the APOE groups, second (model ASTD) differences be-
tween the diagnostic groups, and third (model ASTGD) differences
according to both of these factors simultaneously. A fourth model
(model ASTGAb) investigated APOE status and CSF Ab 42 concen-
tration as predictors of rates of WMH volume progression. Wald
tests were used to compare rates of change between groups after
adjustment for covariates. Fitted group-speciﬁc mean rates of
change (and 95% CI), standardized to a 50/50 mixture of males and
females aged 72.2 with a TIV of 1552 mL, were computed and back-
transformed from each model.
Both cross-sectional and longitudinal analyses were also per-
formed adding systolic blood pressure and diabetes status as
additional covariates, treating these in the sameway as age, sex and
TIV in all models. However, since hypertension and diabetes are
associated with WMH volumes, and are likely on the causal
pathway between APOE status and WMH levels, these results are
presented in supplementary analyses. Finally, in order to under-
stand whether length of follow-up inﬂuenced rate of WMH accu-
mulation we added this variable as an additional covariate in all
longitudinal models.
3. Results
3.1. Demographic results
The inclusion criteria led to the selection of 339 subjects that
collectively had 1620 scans. The number of acquired time points per
Table 1
Demographic ﬁndings across APOE and diagnostics
Criterion Diagnosis APOE status
32 33 42 43 44 Global
Number total (female) NC 11 (6) 56 (29) 0 (0) 18 (9) 3 (3) 88 (47)
EMCI 14 (11) 76 (39) 3 (2) 52 (31) 4 (4) 149 (87)
LMCI 8 (3) 27 (15) 2 (0) 24 (7) 11 (6) 72 (31)
AD 0 (0) 9 (6) 1 (1) 14 (9) 6 (5) 30 (21)
Global 33 (20) 168 (89) 6 (3) 108 (56) 24 (18) 339 (186)
Age, y; mean (SD) NC 73.3 (6.2) 74.2 (5.8) / 73 (8) 78.1 (9.7) 74 (6.4)
EMCI 68.7 (6.6) 71.6 (7.2) 75.3 (5.7) 69.7 (7.2) 68.4 (5.1) 70.7 (7.1)
LMCI 78.4 (9.5) 71.4 (7.5) 64.3 (2) 71.4 (8.1) 70.6 (7.2) 71.9 (8.1)
AD / 78.8 (6) 71.1 (0) 74.6 (7.3) 70.1 (7.2) 74.8 (7.3)
Global 72.6 (8) 72.8 (7) 71 (6.5) 71.3 (7.7) 71.1 (7.3) 72.2 (7.3)
TIV, mL; mean (SD) NC 1497 (133) 1530 (169) / 1543 (152) 1680 (46) 1534 (160)
EMCI 1604 (167) 1564 (123) 1537 (81) 1565 (165) 1720 (45) 1572 (143)
LMCI 1579 (148) 1553 (158) 1435 (92) 1516 (201) 1492 (127) 1531 (167)
AD / 1568 (178) 1510 (0) 1557 (174) 1537 (131) 1555 (159)
Global 1562 (155) 1551 (148) 1498 (83) 1549 (171) 1565 (141) 1552 (155)
Study duration, month; mean (SD) NC 25.8 (3.5) 23.1 (7.4) / 21.9 (4.9) 25.3 (0.6) 23.3 (6.5)
EMCI 25.1 (11.7) 26.1 (10.4) 28.3 (16.6) 27.4 (12.1) 30.8 (12.2) 26.6 (11.2)
LMCI 22.8 (5.8) 23.9 (5.6) 25.5 (0.7) 23.4 (8.1) 19.1 (6) 22.9 (6.6)
AD / 14.6 (4.1) 12 (0) 15.8 (5.9) 20.5 (6.2) 16.2 (5.7)
Global 24.8 (8.2) 24.1 (8.9) 24.7 (12.3) 24.1 (10.4) 22.2 (7.9) 24 (9.3)
Ab ng/mL; mean [SD; N] NC 220 (53; 10) 201 (43; 53) / 173 (42; 15) 111 (42; 3) 194 (48; 81)
EMCI 216 (42; 10) 198 (47; 73) 115 (0; 1) 170 (48; 50) 121 (14; 3) 187 (50; 137)
LMCI 193 (43; 8) 196 (45; 26) 129 (51; 2) 138 (33; 23) 114 (31; 11) 162 (51; 70)
AD / 156 (52; 9) / 143 (41; 14) 102 (10; 6) 139 (45; 29)
Global 211 (46; 28) 196 (46; 161) 125 (37; 3) 160 (45; 102) 111 (26; 23) 179 (52; 317)
WMH, mL; median [IQR] NC 0.98 [0.72, 1.85] 0.99 [0.54, 2.51] / 1.38 [0.84, 3.92] 2.07 [1.84, 12.65] 1.10 [0.65, 2.75]
EMCI 0.77 [0.33, 2.42] 1.23 [0.65, 4.79] 0.40 [0.30, 12.68] 1.69 [0.36, 4.23] 0.90 [0.51, 10.30] 1.23 [0.50, 4.27]
LMCI 5.55 [3.26, 11.75] 1.70 [0.83, 3.95] 1.62 [0.47e2.76] 0.97 [0.50e4.32] 2.18 [1.04, 6.22] 1.78 [0.73, 5.49]
AD / 5.56 [1.88, 6.30] 1.05 [1.05, 1.05] 3.05 [1.33, 5.32] 0.61 [0.30, 3.05] 2.66 [1.06, 5.56]
Global 1.25 [0.71, 3.95] 1.32 [0.67, 4.21] 0.76 [0.40, 2.76] 1.63 [0.50, 4.26] 1.71 [0.75, 4.15] 1.36 [0.61, 4.25]
Key: AD, Alzheimer’s disease; Ab, Ab CSF level; EMCI, early mild cognitive impairment; IQR, interquartile range; LMCI, late mild cognitive impairment; N, number; NC, normal
controls; SD, standard deviation; TIV, total intracranial volume; WMH, white matter hyperintensity.
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of time from baseline assessment varied from 11 to 52 months
(mean 24, SD 9.3). Table 1 shows the demographics of the study
population by genetic status and diagnostic group. As expected, the
AD subjects had lower CSF Ab 42 concentrations than control
subjects, with the MCI subjects having intermediate values
(AD < LMCI < EMCI < NC). CSF Ab 42 concentrations were lower in
subjects with an APOE ε4 allele (44 < 42< 43 < 33). Although age
was comparable across APOE status, EMCI and LMCI were on
average younger than NC and AD.
Volumes using our method and the method from UC Davis at
ﬁrst available measurement were strongly associated (Pearson
correlation ¼ 0.9, Spearman ¼ 0.95). Absolute volume differences
were apparent between methods with our method typically pro-
ducing smaller values than UC Davis’ method. For low lesion vol-
umes, the geometric mean of the ratio was 0.4 with a 95% reference
range of [0.1, 1.2]. Analogous results for high volumes (greater than
the median) were 0.6 with a 95% reference range of [0.3, 1.1].
3.2. Cross-sectional associations of WMH
The baseline data are summarized in Table 2. There was evi-
dence (p ¼ 0.016, model ASTD) that the volume of WMH differed
between the diagnosis severity groups, the difference being driven
mostly by the low volumes observed in NC compared with the 3
other groups. Although the mean WMH volume in the AD group
was slightly lower than that in the EMCI and LMCI groups, these
differences were not statistically signiﬁcant and the 95% conﬁdence
interval for the AD group mean was wide, reﬂecting the fact that
this group contains the fewest subjects. Similar results were seen
when the differences between the diagnostic groups were adjusted
for APOE status (p-value from joint test of differences ¼ 0.033,model ASTGD). Considering the Ab 42 level as a continuous marker
also provided evidence of an association (p<0.0005) with WMH
volume when adjusting for APOE (model ASTGAb).
Across APOE status, an increase in WMH volume with the
number of ε4 alleles was observed, although this was not statisti-
cally signiﬁcant when APOE was considered with or without
adjustment for diagnostic group or Ab. In all these models, the as-
sociations with age and TIV were signiﬁcant (p < 0.001), and the
gender difference was signiﬁcant for model ASTG (p ¼ 0.013) such
that females tended to have more WMH. There was no evidence
that diabetes was related to WMH volume, but there was evidence
of an association for systolic blood pressure with each 10-mm Hg
increase associated with a 12% (95% CI [4.8, 21.1]) increase in vol-
ume. The inclusion of these factors as covariates however did not
materially alter the pattern of results (see Supplemental Material).
3.3. Models of longitudinal WMH volume change
Table 3 summarizes the results for the longitudinal assessment
of the WMH rate of change. Evolution rates are presented as stan-
dardized mean values of percentage change in volume per year,
with the standardized population being a 50:50 mix of males and
females having the mean value of age and TIV across all
participants.
There was strong evidence (p ¼ 0.0002) that mean rates of
change differed between the APOE groups with the largest mean
rate in the APOE ε4ε4 group and the lowest in the APOE ε4ε2 group.
The standardized mean rate in the APOE ε4ε4 group (22.5%/year CI
[14.4e31.2]) was signiﬁcantly higher than that in each of the other
groups (10.0%/year [6.7e13.4] in the ε4ε3 group and 6.6%/year [4.1,
9.3] in the ε3ε3 group, 2.8%/year [2.6 to 8.5] in the ε3ε2 group
and 3.2%/year [14.8 to 9.9] in the ε4ε2 group). The rates in the
Table 2
Baseline models: effects of covariates on differences in WMH volumes across diagnostic groups and APOE genotypes when adjusting for age, sex, and TIV
Models Number (Ab) APOE Diagnosis
32
33 (28)
33
168 (161)
42
6 (3)
43
108 (102)
44
24 (23)
NC
88 (81)
EMCI
149 (137)
LMCI
72 (70)
AD
30 (29)
ASTG Mean, CI 1.54 [1.06, 2.23] 1.44 [1.22, 1.70] 1.42 [0.59, 3.40] 1.69 [1.37, 2.07] 2.12 [1.36, 3.29] NA
Overall p-value 0.5069
Pairwise /
ASTD Mean, CI NA 1.15 [0.92, 1.44] 1.67 [1.40, 2.00] 1.92 [1.49, 2.46] 1.71 [1.15, 2.52]
Overall p-value 0.0157
Pairwise EMCI versus NC*; LMCI versus NC**
ASTGD Mean, CI 1.57 [1.07, 2.30] 1.49 [1.23, 1.80] 1.28 [0.54, 3.04] 1.64 [1.32, 2.03] 1.98 [1.27, 3.08] 1.17 [0.86, 1.59] 1.70 [1.31, 2.21] 1.88 [1.39, 2.52] 1.64 [1.07, 2.52]
Overall p-value 0.7786 0.0331
Pairwise / EMCI versus NC*; LMCI versus NC**
ASTGAb Mean, CI 2.09 [1.38, 3.15] 1.58 [1.33, 1.89] 1.08 [0.31, 3.73] 1.50 [1.21, 1.87] 1.49 [0.91, 2.41] NA
Overall p-value 0.6996
Pairwise /
p-values: *p < 0.05; **p < 0.01.
Values are for a standardized 50/50 mixture of males and females at age 72.2 y with a TIV of 1552 mL. Results are presented back-transformed to their original scale.
Model covariates: ASTD, age sex TIV diagnosis; ASTG, age sex TIV genetic status; ASTGAb, age sex TIV genetic status Ab level; ASTGD, age sex TIV diagnosis genetic status. Key: AD, Alzheimer’s disease; CI, conﬁdence interval;
EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; NA, not applicable; NC, normal control; TIV, total intracranial volume.
Table 3
Longitudinal models: effect of baseline predictors on differences in WMH volume change when adjusting for age, sex, and TIV
Models Number (Ab) APOE Diagnosis
32
33 (28)
33
168 (161)
42
6 (3)
43
108 (102)
44
24 (23)
NC
88 (81)
EMCI
149 (137)
LMCI
72 (70)
AD
30 (29)
ASTG %Change/year CI 2.80 [2.58, 8.47] 6.64 [4.09, 9.26] 3.21 [14.76, 9.91] 9.98 [6.66, 13.40] 22.54 [14.43, 31.22] NA
Overall p-value 0.0002
Pairwise 32 versus 43*; 32 versus 44***; 33 versus 44***; 42 versus 44**; and 43 versus 44**
ASTD %Change/year CI NA 5.81 [2.15, 9.59] 6.57 [3.86, 9.36] 12.54 [8.24, 17.02] 14.65 [5.97, 24.03]
Overall p-value 0.0303
Pairwise EMCI versus LMCI*; NC versus LMCI*
ASTGD %Change/year CI 3.88 [1.91, 10.01] 7.96 [4.65, 11.36] 3.21 [14.82, 9.98] 10.76 [7.00, 14.65] 21.69 [13.63, 30.31] 5.25 [0.56, 10.16] 5.92 [1.99, 10.00] 10.80 [5.96, 15.87] 9.76 [1.09, 19.17]
Overall p-value 0.0016 0.1811
Pairwise 32 versus 43*; 32 versus 44***; 33 versus 44**; 42 versus 43*; 42 versus 44**; 43 versus 44* /
ASTGAb %Change/year CI 6.10 [0.24, 12.32] 7.21 [4.54, 9.95] 10.59 [24.53 , 5.92] 9.16 [5.79, 12.63] 20.22 [11.79, 29.28] NA
Overall p-value 0.0061
Pairwise 32 versus 44*; 33 versus 44**; 42 versus 43*; 42 versus 44**; 43 versus 44*
p-values: *p < 0.05; **p < 0.01; ***p < 0.001.
Standardized percentage changes are presented along with the conﬁdence intervals. Values are standardized to a 50/50 mixture of males and females of age 72.2 y with a TIV of 1552 mL.
Model covariates: ASTD, age sex TIV diagnosis; ASTG, age sex TIV genetic status; ASTGAb, age sex TIV genetic status Ab level; ASTGD, age sex TIV diagnosis genetic status. Key: AD, Alzheimer’s disease; CI, conﬁdence interval;
EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; NA, not applicable; NC, normal control; TIV, total intracranial volume.
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Fig. 3. Longitudinal segmentation for 2 LMCI subjects with APOE status 33 (ﬁrst row) and 44 (second row) with same lesion load at baseline. For each subject, the FLAIR image and
the corresponding lesion segmentation (red ﬁlled) are presented for the baseline (left) and after 2 years (right). Note the faster rate of accumulation for the homozygous APOE ε4
subject (right). Abbreviation: FLAIR, ﬂuid attenuated inversion recovery; LMCI, late mild cognitive impairment. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the Web version of this article.)
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The progression in ε4ε2 group appeared lower than that for the
ε4ε3 group, although this was not formally statistically signiﬁcant
(p ¼ 0.055). Due to the very small sample size, the CI for the ε4ε2
group was very large. Adjustment for either diagnostic group
(model ASTGD) or Ab status (model ASTGAb) slightly attenuated the
differences between the groups without altering the overall
pattern. In the latter model, the dependency of the rate of change
on the CSF Ab level was just formally statistically signiﬁcant
(p < 0.041 for interaction with time).
Rates of change also appeared to increase with diagnosis
severity (AD > LMCI > EMCI > NC) (p ¼ 0.03, model ASTD) ranging
from a mean rate of 5.6%/year in the NC to 14.8%/year for the AD.
This effect was no longer signiﬁcant when adjusting additionally for
APOE status (p ¼ 0.18). There was no evidence that diabetes or
systolic blood pressure was related to rate of change, and the in-
clusion of these factors as covariates did not materially alter the
pattern of results (see Supplemental Material).
There was no evidence that the length of follow-up inﬂuenced
the rate of WMH accumulation (p-value >0.5, all tests).
Fig. 3 presents the evolution in WMH for 2 LMCI subjects with
the same WMH load at baseline, 1 with ε33 and the other with ε44.
Images are shown at baseline and after 2 years.4. Discussion
This longitudinal study shows a strong association between the
APOE status and the rate of WMH volume accumulation. We
observed an increased rate of change in the homozygous 44
compared to the 33 and 43 carriers in a cohort with relatively low
vascular risk factors and WMH burden at baseline. This study
included healthy control subjects, people with MCI, and individuals
with an AD diagnosis. These ﬁndings were observed independently
of diagnosis, and when adjusted for CSF Ab 42 levels, although the
latter adjustment did modify the effect size.In the ADNI study, exclusion criteria were designed to limit the
amount of vascular disease using a threshold of 4 on the Hachinski
score. Therefore, results obtained from this sample may not
necessarily generalize to the population at large. For instance, the
change of 22% per year observed for the APOE ε4ε4 group might be
less likely to occur at higher initial lesion loads (with a larger de-
nominator). The bias toward a vascular riskefree population may
further explain why no statistically signiﬁcant differences at base-
line were observed in our sample with respect to APOE status.
Compared with the general population, this cohort appears
enriched in subjects carrying APOE ε4 alleles mostly in the MCI
group, which may have helped in extracting relevant patterns and
allowed the distinction between heterozygous ε4ε3 and homozy-
gous ε4ε4. In addition, the differences observed in terms of study
length for the LMCI and AD groups may have led to an underesti-
mation of the observed pattern differences. In the case of the AD
population, an additional selection bias might be added since
subjects accumulating higher loads of WMH and AD pathology may
drop out more quickly than those with few WMH; in ADs, 4 time
points may be more difﬁcult to achieve. Despite these potential
limitations, a tendency for increased WMH volume and rates of
change with diagnostic severity was still observed.
Ensuring the appropriate modeling of biological processes is not
trivial. A variety of different ways of modeling change in WMH are
used in the literature making comparisons difﬁcult across studies.
Most studies calculate absolute changes on an untransformed scale.
However, since there is evidence that WMH changes are positively
related to baselineWMH volume load in both normal and dementia
populations (Sachdev et al., 2007; Schmidt et al., 2003), we chose to
analyze changes on a log scale since they implicitly allow the
magnitude of absolute change to be related to baseline level.
Our ﬁnding that different patterns of WMH evolution were
related to APOE status is consistent with previously reported results
(Godin et al., 2009) in normal aging, with a much higher rate of
increase in subjects homozygous for APOE ε4 compared with het-
erozygous subjects or noncarriers. The observation of no
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erozygous 43 and homozygous 33 may be taken as a possible
explanation for disagreements regarding the link of APOE ε4 and
WMH evolution since in some studies the population was simply
dichotomized into carriers and noncarriers (Lo and Jagust, 2012).
The different strengths observed with the covariates for the 43 and
33 carriers may reﬂect potential differences in the pathological
process between these 2 groups.
The association between amyloid pathology, APOE, and WMH
probably reﬂects the link between Ab, APOE ε4, and CAA (Haglund
and Englund, 2002; Verghese et al., 2011). Since a similar tendency
was observed after adjustment for diagnostic group or Ab level, the
additional effects of APOE on the vasculature, independently of
amyloid, are likely to account for the much faster increase in WMH
for subjects homozygous ε4 subjects; although amyloid has an in-
dependent effect in itself, as indicated by the signiﬁcant interaction
term.
Although the synergetic circle linking WMH, Ab, and amyloid
deposition is widely documented (Donahue and Johanson, 2008;
Gupta et al., 2015; Verghese et al., 2011; Zlokovic, 2011), other ex-
planations for the relationships between APOE status and WMH
have been suggested. The APOE ε4 allele has been linked with the
permeability of the blood-brain barrier (BBB) andwith a decrease in
the tight junctions of the blood vessels’ endothelium (Nishitsuji
et al., 2011). An increased permeability could in turn lead to neu-
roinﬂammatory processes, which may contribute to the develop-
ment ofWMH. The dose-dependent associationwith the number of
ε4 alleles could be linked to the hypothesis of the potential pro-
tective effect of allele ε3 on the BBB with respect to neuro-
inﬂammation (Bell et al., 2012). Furthermore, APOE ε4 has been
associated with a decrease in glucose uptake, thus leading to
deprived regions more vulnerable to ischemia (Alata et al., 2014).
APOE ε4 homozygotes have also been associated with a reduction in
capillary surface (Salloway et al., 2002) in AD; this reduction would
directly affect the blood supply in white matter thereby promoting
the development of WMH lesions. The association of APOE ε4 with
microbleeds (Yates et al., 2014) could be related to the exacerbated
deleterious effects of vascular risk factors on WM in APOE ε4 car-
riers (De Leeuw et al., 2004; Wang et al., 2015). The possible joint
effects and interaction of vascular risk factors such as hypertension
and APOE ε4 on the blood vessels are therefore in need of further
investigation with respect to the development of WMH.
So far, cross-sectional studies have reported contradictory
ﬁndings regarding the relationship between APOE ε4 and WMH.
This is further illustrated here by the absence of evidence of a dif-
ference across genetic status at baseline while signiﬁcantly
different rates of change were observed. This ﬁnding strongly
supports the need to better understand the time course and
developmental pattern of pathological processes. Cross-sectional
studies need to consider age imbalances between groups because
it is well understood that increasing age has a strong association
with WMH accrual (van Dijk et al., 2008). In our study, we chose to
adjust for age as is done in most WMH accrual studies (Godin et al.,
2009). This age adjustment explains why the AD group have larger
WMH volumes than the somewhat younger late MCI group before
(Table 1), but not after age adjustment (Table 2). Limitations of
cross-sectional studies may be partially overcome by the applica-
tion of longitudinal models.
One of the main strengths of this study is the use of a novel
longitudinal method of WMH assessment developed for this pur-
pose. The average image on which a generative model is built en-
ables the reduction of measurement noise and accounts for the
within-subject correlation. Accounting for such correlation
instead of simply applying cross-sectional methods to serial scans
for quantitative assessment has been shown to reduce themeasurement variability (Reuter et al., 2012). Furthermore, the
creation of an average image in amid-space overcomes the problem
of a bias toward a speciﬁc time point (Fox et al., 2011; Reuter and
Fischl, 2011). Finally, the use of the generative model to constrain
the segmentation at each time point allows subtle changes to be
measured while maintaining robustness.
This study has a number of limitations. Owing to the complexity
of the possible biophysiological interactions between amyloid
compounds and apolipoprotein, any statistical conclusions should
be treated cautiously. As such, CSF level of Ab-42 used as a surrogate
disease marker for AD pathology (Andreasen et al., 1999) is also
known to be related toWMH (Stenset et al., 2006). Use of CSFAb-40
measures, more associated to vascular deposition, may be infor-
mative of the pathological process. Further work is thus needed to
help disentangle WMH progression and CSF Ab-42 level changes in
the pathogenesis of Alzheimer’s disease. Moreover, only global
WMH loads were considered here, but regional assessment of the
lesion growth and differences in pattern across regions could
improve our understanding of the complex relationship between
APOE, AD, and vascular pathology. Allele ε2 carriers were included
in this study, and results suggested a protective effect of allele ε2,
but the very low prevalence of this allele makes the investigation
difﬁcult. Although a similar link between the allele ε2 and WMH
has been reported (Gesierich et al., 2016), the very limited number
of subjects means our results should be considered very cautiously.
In particular, given the 95% CI found for the 42 group (only 6 sub-
jects), the mean negative accrual of WMH cannot be interpreted as
signiﬁcantly different from 0. This is mostly representative of the
difﬁculty to represent relative changes for very small measured
volumes. Caution in the interpretation is also warranted here with
respect to the ε4 carriers because only 24 homozygous 44 partici-
pants were included in the study.
In conclusion, this study shows the impact of APOE ε4 on the rate
ofWMH accrual over and above diagnosis of AD. Carriage of a single
ε4 allele with a complementary allele ε3 gave a nonsigniﬁcant
additional increase of 3% per year, whereas homozygous carriers
had a signiﬁcant additional increase of 16% per year compared with
ε3 homozygotes. APOE ε4, especially when in the homozygous form,
is an important independent factor in the progression of WMH.
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